← All Dossiers
Mantis Bio (FKA Louiza Labs) – Seed
Funded Healthcare and Life Sciences / Deeptech · Seed · SH Check $500K
Dossier generated 2026-07-12 by /deal-dossier  ·  Deal record: recGggs1xddH4NmCH  ·  Source: Airtable appjxAR3LPe3fkHOp

One-Liner & Thesis

Mantis Bio (formerly Louiza Labs) builds physics-based, high-fidelity synthetic human patients that let medical device, AI, and sports-medicine teams test on virtual anatomy instead of animals, cadavers, and scarce clinical data. The wedge is a proprietary physics engine that produces behaving, instrumented organ-level digital twins: a beating heart took roughly one week to program on top of a year of underlying research, and each new organ takes about a week thereafter (2025-08-28 note). The company sells these as datasets and per-seat model licenses. The insight is that the largest medical players still validate on pig hearts, so a scalable synthetic alternative can compress FDA timelines and remove the ethical and cost friction of physical testing.

Validation is real and commercial: as of the 2025-10-23 note the company had signed a $900K, two-year Cleveland Cavaliers contract for Eastern Conference exclusivity, was cashflow positive, and was taking in-person meetings with the Knicks and Nets, with a Johnson & Johnson $500K shoulder-model discussion in the pipeline (2025-08-28 note). StoryHouse committed $500K from Fund II on the same terms as lead Decibel Ventures: a $5M priced Series Seed at a $15M pre / $20M post valuation, buying 344,210 shares at a $1.4526 Series Seed price (Deal Terms; investment dated 2025-11-24). Georgia notably lowered the round valuation from the earlier $28M-post Decibel SAFE to a $20M-post priced round to reward Decibel for navigating her co-founder separation (2025-10-23 note).

Investment Score & Recommendation

72/ 100
INVEST

The biggest driver is a rare, technically singular founder attacking a large, fast-growing synthetic-biology / digital-twin market with real, cashflow-positive revenue this early. The biggest drag is concentration and key-person risk: a solo founder, a two-person team, and revenue anchored on a single professional-sports customer, following a contentious co-founder exit.

Momentum: Accelerating Red flags: 3 / 9 Confidence: Medium
Market & TAM8/10
25% weight
Team & Founder7/10
25% weight
Product & Traction7/10
20% weight
Deal Terms & Return6/10
20% weight
VC Syndicate8/10
10% weight

Deal

Round Size
$5.0M
Valuation (Pre / Post)
$15M pre / $20M post
Lead Investor
Decibel Ventures ($4M)
Co-Investors
Y Combinator
SH Check
$500K — 344,210 shares @ $1.4526
Fund
StoryHouse Fund II
Funding Round
Seed (priced Series Seed)
SH Investment Date
2025-11-24

Company Snapshot

Sector
Healthcare and Life Sciences, Biotech, AI
Location
Bay Area, California
Headcount
2
Year Founded
2025
Total Raised
$7.2M (all rounds, per 2026-04-29 note)
Website
mantisbiotech.com
Status
Private

Market Size

$3.55B
Healthcare Digital Twins TAMWeb
by 2030, from $903M in 2024
25.9%
CAGRWeb
2025–2030
$150B
Broader Digital Twin MarketWeb
by 2030, ~48% CAGR
Early
Timing

Interpretation: the healthcare-specific digital-twin segment is small today but among the fastest-growing slices of a very large digital-twin market, driven by AI-training data scarcity, regulatory pressure to reduce animal testing, and the FDA's own validation of simulated anatomy (Dassault's Living Heart). Mantis is early in a market where the medical-device design-and-testing sub-segment is projected to grow fastest, so timing favors a synthetic-data-native entrant.

Competition

PlayerPositioningFunding / StageEdge vs. them
Mantis BioPhysics-engine multi-organ digital twins; LLM-routed synthetic biomedical datasets; sports-medicine wedge into devices & pharmaSeed, $20M post; $7.2M raised
Unlearn.AIAI digital twins for synthetic control arms in clinical trialsSeries C, $50M (Altimeter)Mantis targets device / pre-clinical validation, not just trial control arms
Dassault SystèmesFDA-validated Living Heart Project; simulation incumbentPublicStartup speed and per-organ generation vs. legacy CAD-style modeling
Tempus / InsilicoData-driven patient twins (oncology) and AI drug discoveryPublic / late-stageMantis is physics-first synthetic anatomy vs. genomics / data-mining approaches

Moat: a physics engine that generates behaving, instrumented organ twins in roughly a week each, plus retained model IP and patents (2025-07-17 note), creates a compounding data-and-simulation asset that is hard to replicate without the founder's underlying research.

Traction

$900K
Cavs ContractInternal
2-year, signed (2025-10-23)
$450K
Est. LTM RevenueInternal
Positive
CashflowInternal
as of 2025-10-23 note
28 mo
Expected RunwayInternal

Exit Potential

Strategic M&A
Likely Path
6–9 yr
Time to Liquidity
High-var.
Return ScenarioInternal

Most probable exit is strategic acquisition by a medical-device or life-sciences-software incumbent (Johnson & Johnson, Medtronic, and Stryker were cited as roadmap targets in the 2025-08-28 note; Dassault Systèmes and Tempus are natural simulation / data acquirers). Recent comparable financing signal: Unlearn.AI's $50M Series C for synthetic-trial digital twins Web shows deep-pocketed appetite in the category. At a $20M-post entry, a mid-nine-figure medtech outcome would return the position several-fold, though the outcome distribution is wide given the company's stage.

Founders

Georgia Witchel
Founder & CEO · Harvey Mudd '23 (CS), MS Bioengineering (UW)
Founder and CEO of Mantis Bio, building high-fidelity synthetic human patients to power AI training and robotic protocol validation. A savant-type technical founder: a former US Olympic ice climber (homeschooled to train, competing as a junior before an injury), a published author and painter, who entered Harvey Mudd as a high-school junior and interned at Tesla and the Gates Foundation, and previously founded a Spain-based startup that counted Real Madrid as a customer before it wound down. Decibel's Jon Sakoda described her technical depth, writing differential equations to simulate anatomy, as exceptional relative to typical YC founders (2025-09-22 reference call). Now the sole founder after co-founder Larissa Tyagi's departure.

Open Questions & Risks

Next Steps

Latest Meeting Notes

2025-10-23 Call Cavs signed, priced round, move to close expand

Catch-up call confirming the new entity, final round terms, and a clear path to close. The Cavaliers contract is signed, the company is cashflow positive, and StoryHouse is invited in on the same priced-round terms as Decibel.

Full note

Next steps: pursue close; Georgia is connecting us with Fenwick for final documents.

Summary: Company continuing to do well. Cavs contract signed for $900K over two years. In NY for Nets and Knicks meetings. Decided to do a priced round and lower the valuation since Decibel was so helpful with the separation, and will include us on those same terms. Separation agreement is finalized; Larissa doesn't own any portion of the company now, which is why Georgia left instead of the other way around. We should close quickly.

Separation: everything is finalized; the reason Georgia left instead of Larissa was so Larissa couldn't own any of the new company, Mantis. Decibel helped navigate everything.

New round: Decibel asked for higher ownership because of their heavy involvement with the CEO leaving, and Georgia obliged. $20M cap priced round, $5M size: Decibel $4M, YC $500K, StoryHouse $500K. She has interest for another $2M she plans to do on a Seed+SAFE at an increased cap (Magic Johnson / Cavs family office).

Business: Cavs contract now signed, $900K over two years. Currently in NY for in-person meetings with the Knicks and Nets; ran a court-side pilot with the Knicks who seemed interested. Company is now cashflow positive and planning to start making hires. She is connecting us with the Fenwick team for the final docs.

Source: Meeting Notes rec81opqfS7hZdPqB
2025-10-10 Call IP carve-out done, solo founder into YC expand

Miles & Georgia call: a full IP carve-out from the ex-co-founder is complete, Georgia enters the next YC batch as a solo founder, and she is preparing a Decibel-led priced round while finalizing the Cavs contract and expanding the team.

Full note

Summary: Georgia finalized a full IP carve-out from her former co-founder, retaining all investors and YC founder status, and will enter YC as a solo founder. She is preparing a Decibel-led priced round while finalizing a $1M, two-year Cavs contract and expanding her team. Miles will introduce her to Fast Break AI once the Cavs contract and insurance are complete.

Company split resolution: full IP carve-out with ex-co-founder Larissa, who kept her original YC investment and 3 angel investors plus YC founder status and the company name. All investors recommended she leave. Georgia entering the YC batch as a solo founder; money being wired soon; all investors transferred over.

Funding status: Decibel wants to lead the priced round, waiting for the YC term-sheet signature to set MFN; no official timeline. Dan Gilbert (Cavs owner) potentially investing $2M; GM Koby suggested holding allocation, no direct follow-up from Dan yet.

Cavs contract: $1M over 2 years for Eastern Conference exclusivity; essentially a blank contract to fill in product specifications; already used by the Cavs with good results; working toward full system integration; platform currently complex and needs simplification for handoff.

Team expansion: hired 3 total (1 FT, 2 contractors pending); planning to use the StoryHouse hiring pipeline. Strategic: a Fast Break AI introduction (they serve the 17 largest sports leagues and are finishing a Series A) was offered, delayed until the Cavs contract is executed and insurance secured.

Source: Meeting Notes recGXVMkNHvRfLpgE
2025-09-24 Call Co-founder dispute escalates, pause investment expand

Georgia called with an update: the Larissa situation is not as smooth as Decibel had suggested. She still wants StoryHouse in on the same terms but advises against signing documents until the exit is fully resolved.

Full note

Next steps: pause investment for now and resume once the Larissa situation is resolved.

Summary: it does not sound like the situation with Larissa is going as smoothly as Jon / Decibel made it seem. Nothing to do right now, but we should not move forward until it is clear the situation is handled and not a risk.

Raw notes: Georgia called to give an update. She is still excited to work with us and will let us invest on the same terms as Decibel, but is busy dealing with the Larissa situation. Larissa has threatened to sue and is lawyering up, and pulled money out of the Decibel accounts. Jon and Decibel are advising Georgia and YC has gotten involved: YC is banning Larissa and kicking her off Bookface. The issue will likely not settle for at least another week. She recommends not signing any investment documents until Larissa is officially gone.

Source: Meeting Notes rec7x3cpsCjWothwv

Deal Timeline

Reference Calls

Two reference calls with Jon Sakoda of Decibel Ventures (lead investor) on 2025-09-22, both referencing founder Georgia Witchel. Sakoda, a former 12-year NEA partner and early backer of Cloudflare, Elastic, and MongoDB, called Louiza / Mantis an exploratory bet outside Decibel's core AI / data / cyber wheelhouse, made on the strength of Georgia's exceptional technical ability. He characterized the Larissa separation as nearly resolved at that time (Larissa to ~5% equity and a $100–150K payout), recommended a priced round with proper governance over continued SAFEs, and confirmed the Cavs / Dan Gilbert family-office interest as strong commercial validation. StoryHouse's takeaway: fewer concerns on the co-founder dynamic and positive team references, but reservations on price (Meeting Notes rec8PFZHkFvv9MO3e, reczod1jbYIqVJ1rv).

Sources

  1. TechCrunch — Mantis Biotech is making 'digital twins' of humans — $7.4M seed led by Decibel, NBA-team anchor customer, current product / positioning.
  2. Grand View Research — Healthcare Digital Twins Market Report — healthcare digital-twins TAM ($903M in 2024 to $3.55B by 2030, 25.9% CAGR).
  3. MarketsandMarkets — Digital Twin Market Report — broader digital-twin market size and growth to 2030.
  4. Biology Digital — Unlearn.AI digital twins — competitor context; Unlearn.AI $50M Series C for synthetic-trial digital twins.
  5. Y Combinator — Mantis company profile — YC-backed digital-twins-of-humans positioning.